Breast cancer resistance protein (Bcrp1/Abcg2) reduces systemic exposure of the dietary carcinogens aflatoxin B1, IQ and Trp-P-1 but also mediates their secretion into breast milk.
暂无分享,去创建一个
A. V. van Herwaarden | A. Schinkel | J. Jonker | E. Wagenaar | G. Merino | Alfred H Schinkel | Els Wagenaar | Barbara N Karnekamp | Gracia Merino | Johan W Jonker | Antonius E van Herwaarden | Barbara Karnekamp
[1] L. Doyle,et al. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2) , 2003, Oncogene.
[2] H. M. Martins,et al. Aflatoxin M1 in yoghurts in Portugal. , 2004, International journal of food microbiology.
[3] F. X. Bosch,et al. Policy forum: public health. Reducing liver cancer--global control of aflatoxin. , 1999, Science.
[4] Å. Andreassen,et al. Neonatal exposure to the food mutagen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine via breast milk or directly induces intestinal tumors in multiple intestinal neoplasia mice. , 1999, Carcinogenesis.
[5] Alfred H. Schinkel,et al. Human Breast Cancer Resistance Protein: Interactions with Steroid Drugs, Hormones, the Dietary Carcinogen 2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and Transport of Cimetidine , 2005, Journal of Pharmacology and Experimental Therapeutics.
[6] B. Ruebner,et al. Carcinogenicity of dietary aflatoxin M1 in male Fischer rats compared to aflatoxin B1. , 1987, Cancer research.
[7] J. Schellens,et al. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. , 2000, Journal of the National Cancer Institute.
[8] F. X. Bosch,et al. Reducing Liver Cancer--Global Control of Aflatoxin , 1999, Science.
[9] Jos H Beijnen,et al. The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. , 2003, Cancer research.
[10] M. Rudnicki,et al. Side population cells from diverse adult tissues are capable of in vitro hematopoietic differentiation. , 2002, Experimental hematology.
[11] L. A. Dostal,et al. Transfer of di(2-ethylhexyl) phthalate through rat milk and effects on milk composition and the mammary gland. , 1987, Toxicology and applied pharmacology.
[12] S. Ito,et al. Drug excretion into breast milk--overview. , 2003, Advanced drug delivery reviews.
[13] J. Angerer,et al. DEHP metabolites in urine of children and DEHP in house dust. , 2004, International journal of hygiene and environmental health.
[14] T. Dale,et al. The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk , 2005, Nature Medicine.
[15] T. Sugimura,et al. Nutrition and dietary carcinogens. , 2000, Carcinogenesis.
[16] T. Sugimura,et al. Presence of carcinogenic heterocyclic amines in urine of healthy volunteers eating normal diet, but not of inpatients receiving parenteral alimentation. , 1991, Carcinogenesis.
[17] Y. Miki,et al. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. , 2002, Molecular cancer therapeutics.
[18] Y. Miki,et al. C 421 A Polymorphism in the Human Breast Cancer Resistance Protein Gene Is Associated with Low Expression of Q 141 K Protein and Low-Level Drug Resistance 1 , 2002 .
[19] H. Rosing,et al. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[20] A. V. van Herwaarden,et al. Sex-Dependent Expression and Activity of the ATP-Binding Cassette Transporter Breast Cancer Resistance Protein (BCRP/ABCG2) in Liver , 2005, Molecular Pharmacology.
[21] P. D. Josephy,et al. Detection of PhIP (2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine) in the milk of healthy women. , 2001, Chemical research in toxicology.
[22] A. Schinkel,et al. TRANSPORT OF ANTHELMINTIC BENZIMIDAZOLE DRUGS BY BREAST CANCER RESISTANCE PROTEIN (BCRP/ABCG2) , 2005, Drug Metabolism and Disposition.
[23] J. Schellens,et al. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. , 2002, Molecular cancer therapeutics.
[24] G Eisenbrand,et al. Food-borne heterocyclic amines. Chemistry, formation, occurrence and biological activities. A literature review. , 1993, Toxicology.
[25] A. Hall,et al. Aflatoxin M1 in human breast milk from The Gambia, west Africa, quantified by combined monoclonal antibody immunoaffinity chromatography and HPLC. , 1992, Carcinogenesis.
[26] K T Bogen,et al. Cancer risk of heterocyclic amines in cooked foods: an analysis and implications for research. , 1995, Carcinogenesis.
[27] H. Nakauchi,et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype , 2001, Nature Medicine.
[28] E. Schuetz,et al. Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. , 2003, Pharmacogenetics.
[29] A. Schinkel,et al. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. , 2003, Advanced drug delivery reviews.